Scarica l'app Stockscreener
4.7958
0.21%
-0.0042
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACHV Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.80
Aprire:
$4.81
Volume 24 ore:
628.38K
Relative Volume:
0.65
Capitalizzazione di mercato:
$492.76M
Reddito:
-
Utile/perdita netta:
$-54.65M
Rapporto P/E:
-3.7039
EPS:
-1.2948
Flusso di cassa netto:
$-49.47M
1 W Prestazione:
+9.11%
1M Prestazione:
+49.69%
6M Prestazione:
+4.36%
1 anno Prestazione:
+101.26%
Intervallo 1D:
$4.70
$4.85
Intervallo di 1 settimana:
$4.20
$4.895
Portata 52W:
$2.00
$6.025
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Nome
Achieve Life Sciences Inc
Settore
Industria
Telefono
425-686-1500
Indirizzo
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
4.80 | 492.76M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
426.32 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
710.25 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.00 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2025-11-25 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-08-21 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2024-09-27 | Iniziato | Raymond James | Strong Buy |
| 2023-05-10 | Reiterato | Maxim Group | Buy |
| 2021-06-23 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Achieve Life Sciences Inc Borsa (ACHV) Ultime notizie
Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday - MarketBeat
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026 - The Manila Times
Achieve Life will post quarterly results before a May 12 webcast - Stock Titan
Achieve Life Sciences : Corporate Presentation April 2026 (ACHV Corporate Deck April) - marketscreener.com
MSN Money - MSN
Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Achieve Life Sciences : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Board, pay and ownership details at Achieve Life Sciences (NASDAQ: ACHV) - Stock Titan
Goodwin Advises Marshall Wace On Co-Leading Achieve Life Sciences’ $354 Million Private Placement - Mondaq
venBio Global Strategic Fund V Secures Board Seat at Achieve Life Sciences with 9.99% Stake - TradingView
venBio funds take 9.99% Achieve Life stake, add board seat (ACHV) - Stock Titan
Achieve Life Sciences (ACHV) director Royston Aaron reports zero share ownership - Stock Titan
Achieve Life Sciences stock falls after pricing capital raise of $45M via securities offering - MSN
Achieve Life Sciences announces private placement of up to $354M - MSN
Achieve Life Sciences announces proposed public offering; shares down nearly 13% - MSN
Paradigm discloses 9.2% stake in Achieve Life (NASDAQ: ACHV) - Stock Titan
TPG takes 12.6% Achieve Life Sciences (ACHV) stake via $25M structured deal - Stock Titan
TPG-affiliated holders disclose Achieve Life Sciences (NASDAQ: ACHV) shares and warrants position - Stock Titan
Achieve Life Sciences (ACHV) director files Form 3 reporting zero share ownership - Stock Titan
Frazier Life Sciences (ACHV) holds 6.5% stake; warrants disclosed - Stock Titan
Venrock entities disclose 5.2% stake in Achieve Life (ACHV) after April placement - Stock Titan
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Buy" by Brokerages - MarketBeat
Achieve Life Sciences (NASDAQ:ACHV) Stock Rating Upgraded by Canaccord Genuity Group - MarketBeat
Achieve Life Sciences: Up To $354 Million Private Placement Funds Cytisinicline Development And Commercialization - Pulse 2.0
Achieve Life Sciences (ACHV) grants CEO large PRSU, option and RSU awards - Stock Titan
ACHIEVE LIFE SCIENCES (ACHV) CEO files Form 3 reporting zero beneficial ownership - Stock Titan
ACHV Initiates Coverage On Canaccord Genuity -- Rating Set to Bu - GuruFocus
Canaccord Genuity Initiates Coverage on Achieve Life Sciences With Buy Rating, $13 Price Target - marketscreener.com
Achieve Life Sciences flags FDA observations while pushing launch to 2027 for smoking cessation med - MSN
Bothell biotech names new CEO, looks to raise $354 million - The Business Journals
Achieve Life Sciences to Host Meetings During the J.P. Morgan He - GuruFocus
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV), Decibel Cannabis Company (OtherDBCCF) and Eli Lilly & Co (LLY) - The Globe and Mail
Achieve Life Sciences secures $354M financing deal By Investing.com - Investing.com Australia
Achieve Life Sciences names new CEO, adds board members By Investing.com - Investing.com Australia
Achieve Life Sciences Raises Capital, Appoints New CEO - The Globe and Mail
Achieve Life Sciences Secures Up to $354 Million Private Placement to Advance Cytisinicline for Smoking and Vaping Cessation - Minichart
Achieve Life Sciences (ACHV) Secures $354M Through Private Place - GuruFocus
$354M funding and new CEO reshape Achieve Life Sciences (NASDAQ: ACHV) - Stock Titan
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally? - Stocktwits
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Achieve Life Sciences names new CEO, adds board members - Investing.com
Achieve Life Sciences secures $354M financing deal - Investing.com
ACHV Reiterates by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Achieve Life Sciences Inc Azioni (ACHV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Achieve Life Sciences Inc Azioni (ACHV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Oki Mark K | Chief Financial Officer |
Sep 18 '25 |
Sale |
2.92 |
50,060 |
146,175 |
127,940 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Option Exercise |
0.00 |
297,500 |
0 |
358,376 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Sale |
2.92 |
129,501 |
378,143 |
228,875 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
34,100 |
0 |
46,764 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Sale |
2.77 |
14,070 |
38,974 |
32,694 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Option Exercise |
0.00 |
455,000 |
0 |
455,000 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Sale |
2.77 |
139,858 |
387,407 |
315,142 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Option Exercise |
0.00 |
110,000 |
0 |
143,214 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Sale |
2.77 |
27,629 |
76,532 |
115,585 |
| Xinos Jaime | Chief Commercial Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
69,000 |
0 |
95,286 |
5.78%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):